Loading data for OLMA — first visit, this takes a few seconds.

알림

Olema Pharmaceuticals Inc... (OLMA)

NasdaqGS: OLMA · 실시간 가격 · USD

11.32

+0.67 (6.29%)

종가 기준: Aug 18, 2026, 3:59 PM

6.29% (1D)

매수호가	8.05
시가총액	988.72M
매출 (ttm)	n/a
순이익 (ttm)	-204.57M
베타	2.01
EPS (ttm)	-2.12
P/E (ttm)	n/a
선행 P/E	-4.2
P/B (ttm)	2.30
P/S (ttm)	n/a
Earnings Date	Nov 9, 2026

매도호가	13.88
거래량	1,321,752
평균 거래량 (20일)	1,424,543
시가	10.90
전일 종가	10.65
일중 범위	10.77 - 11.32
52주 범위	5.34 - 36.26
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

OLMA 소개

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative ...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Nov 19, 2020

직원 수 150

상장 거래소 NasdaqGS

티커 OLMA

웹사이트 https://olema.com

전체 기업 정보

재무 실적

2025년 Olema Pharmaceuticals의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -162.45M로, 25.47% 증가했습니다.

재무제표

어닝 서프라이즈

Olema Pharmaceuticals가 Aug 10, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.

EPS -0.61 예상치 하회 -0.05, 및 -19.61% 전년 대비 감소.

다음 실적 발표

Olema Pharmaceuticals Inc.의 실적 발표 예정일은 Nov 9, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1개월 전 · Simply Wall St.

Does Olema Pharmaceuticals' (OLMA) Broad Russell Growth Inclusion Reveal a Turning Point in Its Investor Story?

In June 2026, Olema Pharmaceuticals, Inc. was added to multiple Russell growth benchmarks, including the Russell 2000 Growth, 2500 Growth, 3000 Growth, 3000E Growth, Small Cap Comp Growth, and Microca...

2개월 전 · Insider Monkey

How Olema Pharmaceuticals (OLMA) Is Adding Pipeline Depth Behind Its Palazestrant Breast Cancer Bet

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is one of the small-cap stocks with potential to rise 1000 percent. The company gave investors a new pipeline marker on May 21, when it reported initial Phase...

2개월 전 · Simply Wall St.

Olema’s OP-3136 Data Draw Focus To Oncology Pipeline And Valuation Gap

Olema Pharmaceuticals (NasdaqGS:OLMA) reported preliminary Phase 1 data for oral KAT6 inhibitor OP-3136, showing anti-tumor activity in multiple advanced solid tumors. The early readout highlighted tu...

2개월 전 · Stocktwits

Olema Oncology Sees Early Hope As Cancer Drug Shows Tumor Shrinkage In Phase 1 Study

Early ASCO data for OP-3136 pointed to encouraging anti-cancer activity with a clean safety profile, adding momentum to OLMA’s pipeline story.

3개월 전 · Simply Wall St.

Assessing Olema Pharmaceuticals (OLMA) Valuation After Adding Dr. Prakash Raman To The Board

Olema Pharmaceuticals (OLMA) has drawn fresh attention after appointing Prakash Raman, Ph.D., to its Board of Directors. This move puts an experienced oncology and immunology dealmaker closer to the c...

2 페이지 중 1

Olema Pharmaceuticals Inc... (OLMA)